Damora Therapeutics publishes DMR-001 mutant calreticulin antibody presentation

Damora Therapeutics

Damora Therapeutics

DMRA

0.00
  • Damora Therapeutics published a preclinical research presentation on DMR-001, an Fc-null, half-life optimized monoclonal antibody targeting mutant calreticulin in ET and MF.
  • Program highlights included binding affinity of 0.074 nM for Type 1 del52 mutCALR, 0.31 nM for Type 2 ins5.
  • Non-human primate PK half-life was 15 days, versus 3.1 days for a reference mutCALR antibody; expected Phase 1 dosing SC Q4W.
  • Data showed internalization of surface mutCALR, inhibition of pSTAT1 signaling, reduced proliferation; no ADCC or CDC activity reported.
  • A Phase 1/1b study in mutCALR-driven MPN patients is planned to initiate in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.